GNMSF - Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
2024-05-02 18:05:20 ET
Genmab A/S (GMAB)
Q1 2024 Earnings Conference Call
May 2, 2024 12:00 PM ET
Company Participants
Jan van de Winkel – Chief Executive Officer
Anthony Mancini – Chief Operating Officer
Anthony Pagano – Chief Financial Officer
Tahi Ahmadi – Chief Medical Officer
Judith Klimovsky – Chief Development Officer
Conference Call Participants
Sachin Jain – Bank of America/Merrill Lynch
Vikram Purohit – Morgan Stanley
Xian Deng – UBS
Asthika Goonewardene – Truist Securities
Emily Field – Barclays
Peter Verdult – Citigroup
Presentation
Operator
Hello, and welcome to the Genmab First Quarter 2024 Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that'll include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law.
Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
Jan van de Winkel
Hello, and welcome to Genmab's conference call to discuss the company's financial results for the period ending March 31, 2024. With me today to present these results is our CFO, Anthony Pagano; and our Chief Operating Officer, Anthony Mancini. For the Q&A, we will be joined by our Chief Medical Officer, Tahi Ahmadi, and Chief Development Officer, Judith Klimovsky.
As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations, and this slide acknowledges those relationships.
Before we look at our first quarter results, I want to remind you of our consistent track record of success. Our proprietary technologies fuel our robust product pipeline which is both expanding and maturing. And our growing revenue streams allow us to continue to invest in our people and in our pipeline. These are investments that will further accelerate our evolution into a fully integrated biotech innovation powerhouse.
In addition to our existing technologies and mid to late-stage pipeline, a key investment that will enhance our long-term growth profile is the exciting proposed acquisition of ProfoundBio. So let us turn to that briefly now....
Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript